What are Wall Street analysts saying about TG Therapeutics stock?
Here are some recent quotes from research analysts about TG Therapeutics stock:
1. HC Wainwright analysts commented, "Our $20 price target is based on the net present value of our revenue forecast through 2026, applying a 45% probability of success (POS) for ublituximab in CLL, a 45% POS for umbralisib in 25% POS for both ublituximab and umbralisib in NHL. We use a 4x price/sales multiple for these products, an early stage pipeline value of $2.84/share, and fully diluted net cash of $0.75/share to arrive at our price target. Our P/S multiple of 4x is in-line with TG’s peers that range between 2-5x." (1/22/2019)
2. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (11/16/2018)
3. Raymond James analysts commented, "We are maintaining our Strong Buy rating for TG Therapeutics. Today, at the American Academy of Neurology (AAN) 70th Annual Meeting, the company provided an update on the ongoing Phase II study of TG-1101 (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS)." (4/25/2018)
